Cambridge Cluster

Such fun being an angel investor to receive notice of the launch of the company’s first product.  I am just a small investor.  Others have digged deep and the founders have fought hard to make their dream come true.

SimuGen Global announces: SimuGen, a venture-backed pharmacogenomics company focused on predicting human toxicity early on in drug discovery, announced today that it has launched its flagship drug discovery toxicogenomics software product HT-Stream (www.ht-stream.com). HT-Stream is an online high throughput screening software tool for analysing complex in vitro data.

It is all very complex and clever but I think that it uses maths to predict that drugs being developed will have severe side effects.  Stops you going up so many costly blind paths.  Great that they have raised money from Malaysia and are working with a South African company so it is a global business plan resource they need to make sure that we are all winners!  Well done to the team.